A study to assess NTproCNP as a new potential biomarker of atheroma risk and/or severity through clinical studies of blood samples from donors starting statin drug therapy including healthy donors and those with overt coronary artery disease.

Christchurch Heart Institute0 sites65 target enrollmentMay 13, 2013

Overview

No summary available.

Registry

who.int

Start Date

May 13, 2013

End Date

February 28, 2018

Last Updated

6 years ago

Study Type

Interventional

Sex

Male

Sponsor

Christchurch Heart Institute

•Group 1; Males aged 20\-25y. No family history (1st and 2nd degree relatives) of coronary artery disease (CAD), stroke or peripheral vascular disease (PVD). No personal history of high BP, smoking, diabetes, lipid disorders or renal disease. BMI between 18\-25\. Normal BP (\<140 systolic, \<90 diastolic). Normal Blood lipid profile.
•Group 2; Males aged 40\-60y. No family history (1st and 2nd degree relatives) of CAD, stroke or PVD. No personal history of high BP, smoking, diabetes, lipid disorders or renal disease. BMI between 18\-25\. Normal BP (\<140 systolic, \<90 diastolic). Normal Blood lipid profile.
•Group 3; Males diagnosed with overt coronary artery disease aged 40\-60y about to start statin therapy. Allow family history of CAD, stroke or PVD. Allow personal history of high BP, lipid disorder.

•Unwilling or unable to give informed consent.
•Groups 1 \& 2; On medication. BMI \> 25\. Systolic BP \>140, Diastolic BP \>90\. Triglycerides \>1\.7mmol/L.
•Group 3; Subjects who have previously taken statin medication. Subjects with past episodes of heart failure, diabetics receiving insulin, raised plasma creatinine (\> 110umol/L) and metabolic bone disease or recent fracture.